Publication:
Cardiotoxicity of 5-flourouracil: two case reports

dc.contributor.authorsTutkun, A; Inanli, S; Caymaz, O; Ayanoglu, E; Duman, D
dc.date.accessioned2022-03-12T16:59:30Z
dc.date.accessioned2026-01-10T18:36:01Z
dc.date.available2022-03-12T16:59:30Z
dc.date.issued2001
dc.description.abstractCardiotoxicity is a ran but serious side effect of 5-flourouracil (5-FU), The cardiotoxicity incidence of 5-FU is increasing with its frequent use in chemotherapy protocols. To explain the mechanism of this cardiotoxicity, many theories have been suggested by different authors. Most commonly, coronary artery vasospasm and flouroacetate, a toxic metabolite of 5-FU, are considered responsible for the toxicity. Ischemic symptoms and signs related to 5-FU are observed during the late phase of the administration of the drug. The close and careful monitorization of all the patients, especially the ones with pre-existent coronary artery disease, during 5-FU infusion is mandatory. Because there is not a single and effective modality of treatment or prophylaxis for 5-FU cardiotoxicity. the patients should be selected carefully for 5-FU administration and 5-FU infusion should be stopped as soon as a symptom is encountered, (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
dc.identifier.doi10.1016/S0385-8146(00)00112-7
dc.identifier.issn0385-8146
dc.identifier.pubmed11240331
dc.identifier.urihttps://hdl.handle.net/11424/227203
dc.identifier.wosWOS:000168318800016
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofAURIS NASUS LARYNX
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectcardiotoxicity
dc.subject5-flourouracil
dc.subjectchemotherapy
dc.subject5-FLUOROURACIL CARDIOTOXICITY
dc.titleCardiotoxicity of 5-flourouracil: two case reports
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage196
oaire.citation.issue2
oaire.citation.startPage193
oaire.citation.titleAURIS NASUS LARYNX
oaire.citation.volume28

Files